Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

57.36 0.10 −0.17%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a

Arrowhead Pharmaceuticals, Inc. (ARWR) Gross margin

Alert me on Gross margin

Arrowhead Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 June 2026 was 100.0%, down 0.0 percentage points from fiscal 2025 (100.0%). Over the past ten years it has ranged from 100.0% (fiscal 2025) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 100.0% 0.00
FY2024 100.0% 0.00
FY2023 100.0% 0.00
FY2022 100.0% 0.00
FY2021 100.0% 0.00
FY2020 100.0% 0.00
FY2019 100.0% 0.00
FY2018 100.0% 0.00
FY2017 100.0% 0.00
FY2016 100.0% 0.00

Quarterly newest first

Period Gross margin Change (points)
Jun 2026 100.0% 0.00
Mar 2026 100.0% 0.00
Dec 2025 100.0% 0.00
Sep 2025 100.0% 0.00
39 more quarters

Against its own ten years

Low 100.0% High 100.0%
Ten-year median 100.0%
Current reading's percentile 100

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on ARWR